PR(301230.SZ)

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

PR: At this stage, the direct revenue from the company's DiOrion platform drug development services accounts for a small proportion of the company's overall operating income, which does not have a significant impact on the company's overall operating situation

PR released its performance for the first three quarters, with a net profit attributable to the parent company of 34.7496 million yuan, an increase of 127.96%

PR released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 514 million yuan, a year-on-year increase of 31.43%. The net profit attributable to shareholders of the listed company was 34.7496 million yuan, a year-on-year increase of 127.96%. The net profit after deducting non-recurring gains and losses was 27.7095 million yuan, a year-on-year increase of 353.43%. The basic earnings per share were 0.2489 yuan

PR: It plans to distribute 13.754 million yuan in cash for the first three quarters of 2025

PR announced that the company's consolidated net profit for the first three quarters of 2025 was 34.7496 million yuan. As of the board meeting date, the total share capital, excluding repurchased shares, was 138 million shares. The company plans to distribute a cash dividend of 1 yuan for every 10 shares to all shareholders based on the total share capital issued as of the equity registration date, excluding the number of repurchased shares, with an expected cash dividend distribution of 13.754 million yuan. This plan is subject to approval at the third extraordinary general meeting of shareholders in 2025

The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine